Minocycline diffusion into benign prostatic hyperplasia.
Minocycline, a broad-spectrum, highly lipid soluble tetracycline that has generated interest in the treatment of chronic prostatitis, was evaluated for its possible ability to be concentrated in benign prostatic hyperplasia. Drug levels in the prostate, plasma, fat, muscle and urine were measured in patients undergoing open prostatectomy after preoperative intravenous minocycline. The concentrations of the drug in the prostate and serum were close (4.16 versus 3.01 microgram. per gm.), while drug levels in striated muscle and fat were consistently lower (2.92 and 0.77 microgram. per gm). Higher preoperative doses of drug yielded higher tissue levels. Drug delivery closer temporally to the operation yielded higher serum and prostatic levels as opposed to striated muscle and fat, suggesting a rapid diffusion of the drug into benign prostatic hyperplasia.
D000273:Adipose Tissue / Q000378:metabolism; D004058:Diffusion; D006801:Humans; D008297:Male; D008911:Minocycline / Q000378:metabolism*; D009132:Muscles / Q000378:metabolism; D011467:Prostate / Q000378:metabolism; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000378:metabolism*; D013754:Tetracyclines / Q000378:metabolism*
D013754:Tetracyclines; D008911:Minocycline